
If Big Tech earnings deliver, the bull run gets fresh legs
It's tempting to call this a pause for breath—but make no mistake, what follows could determine whether bulls stay in control.
With 59 S&P 500 companies already reporting and a staggering 86% surpassing estimates, according to FactSet's latest, the bar being set is high. It's a message: optimism is winning, but only if it endures.
ADVERTISEMENT
The spotlight now turns to the elite of the elite: Alphabet and Tesla. These two giants, part of the so-called 'Magnificent Seven,' are poised to set the tempo. FactSet forecasts these mega-caps will deliver about 14% year-on-year growth, dwarfing the modest 3.4% gain expected from the remaining 493 S&P members. If they execute, markets could ride that booster straight into orbit.
Look at Alphabet first. Here's a conglomerate that dominates search, YouTube, cloud, and is now making serious AI inroads. Analysts expect around 15% growth in earnings, with cloud revenue expanding in double digits. That's robust by any standard.
However, the test will lie in translating AI investment into sustained profit, and avoiding regulatory traps that could dampen its shine.
Then there's Tesla, which is a polarizing force in the EV and tech arenas. Yes, deliveries are down about 13.5% year-over-year, and earnings are estimated to fall roughly 19–20%, with EPS north of $0.40.
But Elon Musk is doubling down, reportedly sleeping in the office, laser-focused on robotaxi and tech updates. If he delivers on those fronts, sentiment could swing sharply positive, even if top-line figures remind investors of lumpiness in the core auto business.
This is why this phase of earnings feels nothing like a routine check-in. We're perched on a razor's edge: confirmation that growth remains intact—or the first sign that valuations teeter on thin air.
The S&P's forward P/E sits around 22.2, higher than its five- and 10-year norms of 19.9 and 18.4, respectively. That's a premium tied to performance. With 19 quarters of revenue growth already behind us, it's time for proof that earnings can keep pace.
The message from the banks so far paints a picture: financials and healthcare are lifting earnings, while sectors like energy are lagging. But if Alphabet or Tesla stumble, it could offset gains and invite a broader reassessment. Conversely, if they deliver, and perhaps outperform, this rally gains fresh legs.
Why is this crucial? Because the backdrop remains complex. Tariff chatter, Fed policy shifts, geopolitical worries, they're all still in play. But right now, the market isn't fixated on macro headlines. It's banking on this micro foundation: corporate earnings. A strong season builds confidence that transcends volatility.
It's about narrative, too. When the S&P hits new heights just as earnings season begins, there's a constancy in the story. It's not just that the market is high, it's that earnings are expected to follow suit. Beat expectations, and that narrative deepens; miss them, and the rally becomes vulnerable to challenges.
So, here's where we stand: the Opening Act is strong. Momentum is palpable. But what matters most is what happens next. Can the Magnificent Seven deliver? Will Alphabet stave off AI disruption and regulatory spanners? Can Tesla quell concerns about shrinking deliveries and keep investor passion alive through its tech ambition?
Their answers will echo far beyond their own results; they'll shape how investors view the entire S&P.
So buckle up. This week's script will write the next chapter in the bull story. No one wants to see forceful resistance here. The market's high ambitions demand high execution. If that comes, the journey upward continues.
Nigel Green is deVere CEO and Founder
Also published on Medium.
Notice an issue? Arabian Post strives to deliver the most accurate and reliable information to its readers. If you believe you have identified an error or inconsistency in this article, please don't hesitate to contact our editorial team at editor[at]thearabianpost[dot]com. We are committed to promptly addressing any concerns and ensuring the highest level of journalistic integrity.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Zawya
4 hours ago
- Zawya
Trump says he wants Musk and his companies to thrive in US
President Donald Trump said on Thursday he would not destroy Elon Musk's companies by taking away federal subsidies and that he wants the billionaire tech-entrepreneur's businesses to thrive. "Everyone is stating that I will destroy Elon's companies by taking away some, if not all, of the large scale subsidies he receives from the U.S. Government. This is not so!," Trump said in a social media post. "I want Elon, and all businesses within our Country, to THRIVE." Trump's statement follows a public clash with his former close ally on June 5 over his tax bill. Musk warned Tesla investors on Wednesday that U.S. government cuts in support for electric vehicle makers could lead to a "few rough quarters" for the company. A week after the spat in June, Reuters reported the White House had directed the Defense Department and NASA to gather details on billions of dollars in SpaceX contracts to ready possible retaliation against the businessman and his companies. Musk spent more than a quarter of a billion dollars to help Trump win November's presidential election and led the Department of Government Efficiency's chaotic effort to slash the budget and cut the federal workforce. The Tesla CEO left the administration in late May to refocus on his tech empire. Trump and Musk fell out shortly afterward when Musk openly denounced the Republican president's tax-cut and spending bill, leading to threats by Trump to cancel billions of dollars worth of federal government contracts with Musk's companies. Musk's SpaceX had been considered a frontrunner to build out Trump's $175 billion Golden Dome missile defense shield and remains a natural choice for key elements of the project. But sources familiar with the matter told Reuters earlier this week that the administration is expanding its search for partners to build Golden Dome as tensions with Musk threaten SpaceX's dominance in the program. (Reporting by Bhargav Acharya in Toronto; Editing by Doina Chiacu and Philippa Fletcher)


Al Etihad
4 hours ago
- Al Etihad
Tesla shares fall 8% after reporting profit drop
24 July 2025 19:04 NEW YORK (AFP)Tesla shares tumbled more than eight percent early Thursday after it reported lower profits and CEO Elon Musk warned the company faced more potentially "rough" quarters 1350 GMT, Tesla shares were at $30.50, down 8.1 percent. Tesla reported second-quarter profits of $1.2 billion, down 16 percent from the year-ago level, its third quarter in a row in which profits fell.


Gulf Today
5 hours ago
- Gulf Today
5 years after COVID, pharma shares languish
Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies since Donald Trump returned to the White House. Pharma companies' earnings outlook is being obscured by concerns over revived "most-favored-nation" drug pricing rules in the lucrative US market and potential 200% tariffs on pharma imports into the US. Money flooded into drugmakers' shares during the COVID-19 pandemic but more recently there has been an exodus as investors shifted into Big Tech, leaving the sector cheap but unloved, reported Reuters. At 15.9 times forward earnings, healthcare trades 11% below its long-term average and 20% below global equities, its steepest discount in 16 years, just above a record discount in 2009, based on LSEG Datastream data. "We've moved from cautious optimism to cautious pessimism," said Stephanie Aliaga, global market strategist at J.P. Morgan Asset Management in New York. "Valuations have gotten even cheaper, but for a reason," she added, referring to intensifying US policy risks. But some investors are starting to look past the Washington policy fog and at long-term positive drivers, such as aging populations, RNA-based therapeutics, and breakthroughs in weight-loss and diabetes drugs, Reuters reported. Alberto Conca, CIO at Swiss wealth manager LFG+ZEST, has been adding exposure to pharma, biotech and medtech in recent weeks, drawn by strong cash-flow yields and the prospect of US rate cuts boosting this rate-sensitive sector. Interest rate cuts typically support healthcare by lowering R&D funding costs and boosting the value of future cash flows. "These are quality companies with good growth and defensive features being priced as if we're heading into an 'Armageddon scenario', which I believe is unlikely," he said. UK-based M&G Investments has also been selectively adding to healthcare, according to its latest allocation report. Healthcare funds have seen net inflows since 2024, more than reversing the outflows from late 2022 through 2023, fund tracker EPFR data shows. Although year-to-date, inflows total $7.2 billion, down 41% from last year. Innovation is accelerating, pipelines are maturing and M&A is showing signs of picking up — yet stock prices are unmoved. Whether that represents a buying opportunity or a value trap hinges on how and when the policy uncertainty clears, investors said. Historically, healthcare has traded at a modest premium to world stocks, thanks to its defensive profile and steady earnings. But that narrative has unravelled under political pressure from Washington and investors' love of Big Tech. Over the past three years, US healthcare has underperformed the S&P 500 by more than 60 percentage points, making it the worst sectoral performer on Wall Street. Its valuation has deepened to a near-record 27% discount, from parity to the S&P in 2023. "Markets don't like uncertainty, and that shows up in valuations," said Eddie Yoon, healthcare sector leader and portfolio manager at Fidelity Investments in Boston. "Being cheap isn't necessarily a reason to buy. You need a catalyst." For now, that catalyst is elusive. The policy uncertainty makes it difficult to forecast future earnings, he said, though he hopes for more clarity by year-end - potentially also paving the way for more M&A in the industry. Talks with the Trump administration have yet to clarify how and when drug prices will fall, executives from Eli Lilly and Merck said at a May industry conference.